Imunon (NASDAQ:IMNN) Receives Buy Rating from D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They presently have a $29.00 price target on the stock.

Several other equities analysts have also recently weighed in on IMNN. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Imunon in a report on Wednesday, December 11th. EF Hutton Acquisition Co. I raised Imunon to a “strong-buy” rating in a research note on Monday, September 23rd.

Imunon Trading Down 4.2 %

NASDAQ IMNN opened at $0.83 on Thursday. The company has a market cap of $12.04 million, a price-to-earnings ratio of -0.44 and a beta of 2.12. The company has a 50 day moving average of $0.88 and a 200-day moving average of $1.08. Imunon has a 1-year low of $0.48 and a 1-year high of $3.65.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.